Barcelona

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Amyloidosis3 trials
• Chronic kidney disease1 trial
• Epilepsy1 trial
• High blood pressure1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Recruiting3 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Alnylam Pharmaceuticals4 trials
• Dicerna Pharmaceuticals, Inc., a Novo Nordisk company1 trial
• Jazz Pharmaceuticals1 trial

Running trials

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD

  NCT04580420· Phase 2· Dicerna Pharmaceuticals, Inc., a Novo Nordisk company· Source

  Contact: Clinical Trial Coordinator

• Recruiting

  ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

  NCT04561518· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Chronic kidney disease1 recruiting
• High blood pressure1 recruiting

Closed trials

• Terminated

  Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

  NCT04485104· Phase 3· Jazz Pharmaceuticals· Source